Glympse Bio Raises $46.7 Million in Series B Funding Round
July 15 2020 - 12:30PM
Dow Jones News
By Colin Kellaher
Biotechnology startup Glympse Bio Wednesday said it raised $46.7
million in an oversubscribed Series B financing at an undisclosed
valuation.
Glympse said Bill Maris' Section 32 venture-capital firm led the
round, which also included participation from new investors
Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures
and Catalio Capital Management, along with existing investors LS
Polaris Innovation Fund, ARCH Venture Partners, CRV, GreatPoint
Ventures and Gilead Sciences Inc.
The Cambridge, Mass., company founded in 2015 has now raised
$75.3 million.
Glympse said it will use the new funding to support continued
development of its novel biosensor platform in non-alcoholic
steatohepatitis, a chronic liver condition commonly known as NASH,
and to explore the potential of the platform across multiple other
areas, such as oncology and infectious diseases.
Gilead last year announced a deal to use Glympse's biomarker
technology in its NASH clinical programs.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 15, 2020 12:15 ET (16:15 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Feb 2024 to Mar 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2023 to Mar 2024